Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Aclarion Inc ACON

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the... see more

Recent & Breaking News (NDAQ:ACON)

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

GlobeNewswire December 22, 2022

Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

GlobeNewswire December 21, 2022

Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor

GlobeNewswire December 19, 2022

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

GlobeNewswire December 1, 2022

Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV

ACCESS Newswire October 25, 2022

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

ACCESS Newswire October 24, 2022

Aclarion To Present at The LD Micro Main Event XV

Newsfile October 12, 2022

Aclarion Announces Participation at the NASS 37th Annual Meeting

ACCESS Newswire October 10, 2022

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

ACCESS Newswire October 3, 2022

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

ACCESS Newswire September 19, 2022

Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

Newsfile August 4, 2022

Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

ACCESS Newswire July 20, 2022

Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

ACCESS Newswire June 22, 2022

Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering

ACCESS Newswire April 26, 2022

Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering

ACCESS Newswire April 21, 2022